A single intraarticular injection of a tranexamic acid-modified hyaluronic acid (HA/TXA) alleviates pain and reduces OA development in a murine model of monosodium iodoacetate-induced osteoarthritis.

MLA

Brochard, Sybille, et al. “A Single Intraarticular Injection of a Tranexamic Acid-Modified Hyaluronic Acid (HA/TXA) Alleviates Pain and Reduces OA Development in a Murine Model of Monosodium Iodoacetate-Induced Osteoarthritis.” Frontiers in Pharmacology, Sept. 2024, pp. 1–8. EBSCOhost, https://doi.org/10.3389/fphar.2024.1456495.

APA

Brochard, S., Boumédiene, K., Mercier, J., Agin, V., Conrozier, T., & Baugé, C. (2024). A single intraarticular injection of a tranexamic acid-modified hyaluronic acid (HA/TXA) alleviates pain and reduces OA development in a murine model of monosodium iodoacetate-induced osteoarthritis. Frontiers in Pharmacology, 1–8. https://doi.org/10.3389/fphar.2024.1456495

Chicago

Brochard, Sybille, Karim Boumédiene, Jéromine Mercier, Véronique Agin, Thierry Conrozier, and Catherine Baugé. 2024. “A Single Intraarticular Injection of a Tranexamic Acid-Modified Hyaluronic Acid (HA/TXA) Alleviates Pain and Reduces OA Development in a Murine Model of Monosodium Iodoacetate-Induced Osteoarthritis.” Frontiers in Pharmacology, September, 1–8. doi:10.3389/fphar.2024.1456495.